Supercritical fluid particle design for poorly water-soluble drugs (Review)

Current Pharmaceutical Design

Volumn 20, Issue 3, 2014, Pages 349-368

  Sun, Yongda ^a,b  

^a TIANJIN UNIVERSITY   (China)

^b Fisheries Research Institute of Tianjin   (China)

Author keywords

Bio drug particles; Composite particles; Dissolution; Nano micron particles; Polymorphic particles; Poorly water soluble drugs; Solubility; Supercritical fluid particle design

Indexed keywords

BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 84894089607     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990404     Document Type: Review

References (176)

1. Ku MS, Dulin W. A biopharmaceutical classification-based right-first-time formulation approach to reduce human pharmacokinetic variability and project cycle time from first-in-human to clinical proof-of-concept. Pharm Devel Tech 2012; 17: 285-302.
2. Giliyar C, Fickstad DT, Tyavanagimatt S. Challenges and opportunities in oral delivery of poorly water-soluble drugs. Drug Del Tech 2006; 6: 57-63.
3. Amidon GL, Lennernäs H, Shah VP, Crison JR, A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 1995: 12: 413-20.
4. Sakaeda T, Okamura N, Nagata S, et al. Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. Bio Pharm Bull 2001; 24: 935-40.
5. Takagi T, Ramachandran C, Bermejo M, et al. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006; 3: 631-43.
6. Hōrter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Del Rev 2001; 46: 75-87.
7. Chaudhary A, Nagaich U, Gulati N, et al. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: a recent review. J Adv Pharm Edu & Res 2012; 2: 32-67.
8. Kawakami K. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv Drug Del Rev 2012; 64: 480-95.
9. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorlywater soluble compounds using wet media milling technology. Adv Drug Del Rev 2011; 63: 427-40.
10. Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicine: an emerging field. Toxicol Pathol 2008; 36: 21-9.
11. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Disc 2004; 3: 1023-35.
12. Kawabata Y, Wada K, Nakatani M, et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J Pharm 2011; 420: 1-10.
13. Leuenberger H, Lanz M. Pharmaceutical powder technology-from art to science: the challenge of the FDA's Process Analytical Technology initiative. Adv Powder Tech 2005; 16: 3-25.
14. Yu LX, Raw A, Lionberger R, et al. US FDA question-based review for generic drugs: a new pharmaceutical quality assessment system. J Generic Medicines 2007; 4: 239-48.
15. Yu LX, Lionberger RA, Raw AS, et al. Applications of process analytical technology to crystallization processes. Adv Drug Del Rev 2004; 56: 349-69.
16. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res 2008; 25: 781-91.
17. Noyori R. Pursuing practical elegance in chemical synthesis. Chem Communi 2005; 14: 1807-11.
18. Tom JW, Debenedetti PG. Particle formation with supercritical fluids-a review. J Aerosol Sci 1991; 22: 555-84.
19. Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey. J Supercritical Fluids 2001; 20: 179-219.
20. York P, Kompella UB, Shekunov BY, Eds. Supercritical fluid technology for drug product development. New York: Marcel-Dekker 2004.
21. Türk M, Hils P, Helfgen B, et al. Micronization of pharmaceutical substances by the Rapid Expansion of Supercritical Solutions (RESS): a promising method to improve bioavailability of poorly soluble pharmaceutical agents. J Supercritical Fluids 2002; 22: 75-84.
22. Shariati A, Peters CJ. Recent developments in particle design using supercritical fluids. Current Opinion in Solid State and Materials Sci 2003; 7: 371-83.
23. Hakuta Y, Hayashi H, Arai K. Fine particle formation using supercritical fluids. Current Opinion in Solid State and Materials Sci 2003; 7: 341-51.
24. Knez Z, Weidner E. Particle's formation and particle design using supercritical fluids. Current Opinion in Solid State and Materials Sci 2003; 7: 353-61.
25. Reverchon E, Volpe MC, Caputo G. Supercritical fluid processing of polymers: composite particles and porous materials elaboration. Current Opinion in Solid State and Materials Sci 2003; 7: 391-97.
26. Fages J, Lochard H, Letourneau J, et al. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Tech 2004; 141: 219-26.
27. Vemavarapu C, Mollan MJ, Lodaya M, et al. Design and process aspects of laboratory scale SCF particle formation systems. Int J Pharm 2005; 292: 1-16.
28. Yeo SD, Kiran E. Formation of polymer particles with supercritical fluids: A review. J Supercritical Fluids 2005; 34: 287-308.
29. Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poorly soluble active ingredients by supercritical fluid processes: Part I: Micronization of neat particles. Int J Pharmaceutics 2005; 288: 3-10.
30. Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poorly soluble active ingredients by supercritical fluid processes: Part II: Preparation of composite particles. Int J Pharmaceutics 2005; 288: 11-6.
31. Pasquali I, Bettini R, Giordano F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Euro J Pharm Sci 2006; 27: 299-310.
32. Reverchon E, Adami R. Nanomaterials and supercritical fluids. J Supercritical Fluids 2006; 37: 1-22.
33. Bahrami M, Ranjbarian S. Production of micro-and nanocomposite particles by supercritical carbon dioxide. J Supercritical Fluids 2007; 40: 263-83.
34. Tandya A, Mammucari R, Dehghani F, et al. Dense gas processing of polymeric controlled release formulations. Int J Pharm 2007; 328: 1-11
35. Sun Y. Expert review: new technology of supercritical fluid and its application in superfine drugs powder (in Chinese). The Yearbook of China Powder Industry 2007; 181-95.
36. Byrappa K, Ohara S, Adschiri T. Nanoparticles synthesis using supercritical fluid technology-towards biomedical applications. Adv Drug Del Rev 2008; 60: 299-327.
37. Moribe K, Tozuka Y, Yamamoto K. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation. Adv Drug Del Rev 2008; 60: 328-38.
38. Martín A, Cocero M. Micronization processes with supercritical fluids: Fundamentals and mechanisms. Adv Drug Del Rev 2008; 60: 339-50.
39. Daintree LS, Kordikowski A, York P. Separation processes for organic molecules using SCF technologies. Adv Drug Del Rev 2008; 60: 351-72.
40. 2 in the fabrication of polymer systems for drug delivery and tissue engineering. Adv Drug Del Rev 2008; 60: 373-87.
41. Yasuji T, Takeuchi H, Kawashima Y. Particle design of poorly water-soluble drug substances using supercritical fluid technologies. Adv Drug Del Rev 2008; 60: 388-98.
42. Pasquali I, Bettini R, Giordano F. Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Del Rev 2008; 60: 399-410.
43. Mishima K. Biodegradable particle formation for drug and gene delivery using supercritical fluid and dense gas. Adv Drug Del Rev 2008; 60: 411-32.
44. Reverchon E, Adami R, Caputo G, et al. Spherical microparticles production by supercritical antisolvent precipitation: Interpretation of results. J Supercritical Fluids 2008; 47: 70-84.
45. Okamoto H, Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv Drug Del Rev 2008; 60: 433-46.
46. Pasquali I, Bettini R. Are pharmaceuticals really going supercritical? Int J Pharm 2008; 364: 176-87.
47. Cocero MJ, Martín A, Mattea F, et al. Encapsulation and coprecipitation processes with supercritical fluids: fundamentals and applications. J Supercritical Fluids 2009; 47: 545-55.
48. Reverchon E, Adami R, Cardea S, et al. Supercritical fluids processing of polymers for pharmaceutical and medical applications. J Supercritical Fluids 2009; 47: 484-92.
49. Türk M. Manufacture of submicron drug particles with enhanced dissolution behaviour by rapid expansion processes. J Supercritical Fluids 2009; 47: 537-45.
50. Zarena AS, Sankar KU. Design of submicron and nanoparticle delivery systems using supercritical carbon dioxide-mediated processes: an overview. Therapeutic Delivery 2011; 2: 259-77.
51. Naylor A, Lewis AL, Llium L. Supercritical fluid-mediated methods to encapsulate drugs: recent advances and new opportunities. Therapeutic Delivery 2011; 2: 1551-65.
52. Beh CC, Mammucari R, Foster NR. Lipids-based drug carrier systems by dense gas technology: A review. Chem Eng J 2012; 188: 1-14.
53. Tabernero A, Valle EM, Galàn MA. Supercritical fluids for pharmaceutical particle engineering: methods, basic fundamentals and modelling. Chem Eng and Proc 2012; 60: 9-25.
54. Domingo C, Saurina J. An overview of the analytical characterization of nanostructured drug delivery systems: Towards green and sustainable pharmaceuticals: A review. Anal Chim Acta 2012; 744: 8-22.
55. Sheth P, Sandhu H, Singhal D, et al. Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production. Curr Drug Deliv 2012; 9: 269-84.
56. McHugh M, Krukonis V. Supercritical Fluid Extraction. Boston: Butterworth-Heinemann1994.
57. Mukhopadhyay M. Phase equilibrium in solid-liquid-supercritical fluid systems. In: York P, Kompella UB, Shekunov BY, Eds. Supercritical fluid technology for drug product development. New York: Marcel-Dekker 2004; pp.27-90.
58. Subramaniam B, Rajewski RA, Snaveky K. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 1997; 86: 885-90.
59. Garlapati C, Madras G. New empirical expressions to correlate solubilities of solids in supercritical carbon dioxide. Thermochimica Acta 2010; 500: 123-7.
60. Nejad SJ, Abolghasemi H, Moosavian MA, et al. Prediction of solute solubility in supercritical carbon dioxide: A novel semiempirical model. Chemical Eng Res and Design 2010; 88: 893-8.
61. Skerget M, Knez Z, Knez-Hrncic M. Solubility of solids in suband supercritical fluids: A review. J Chem Eng Data 2011; 56: 694-719.
62. De Zordi N, Kikic I, Moneghini M, et al. Solubility of pharmaceutical compounds in supercritical carbon dioxide. J Supercritical Fluids 2012; 66: 16-22.
63. Hannay JB, Hogarth J. On the solubility of solids in gases. Proc Roy Soc 1879; 29: 324-27.
64. Krukonis V. Supercritical nucleation of difficult-to-communute solids. Annual AIChE Meeting, San Fransisco, 1984.
65. Gallagher PM, Coffey MP, Krukonis VJ, et al. Gas antisolvent recrystallization: new process to recrystallize compounds insoluble in supercritical fluids. In: Gallagher PM, Coffey MP, Krukonis VJ, Eds. Supercritical Fluid Science and Technology. Washington, DC: American Chemical Society 1989; pp.334-54.
66. Helfgen B, Türk M, Schaber K. Hydrodynamic and aerosol modelling of the rapid expansion of supercritical solutions (RESS-process). J Supercritical Fluids 2003; 26: 225-42.
67. Huang Z, Sun GB, Chiew YC, et al. Formation of ultrafine aspirin particles through rapid expansion of supercritical solutions (RESS). Powder Tech 2005; 160: 127-34.
68. Türk M, Hils P, Helfgen B, et al. Micronization of pharmaceutical substances by the rapid expansion of supercritical solutions (RESS): a promising method to improve bioavailability of poorly soluble pharmaceutical agents. J Supercritical Fluids 2002; 22: 75-84.
69. Kayrak D, Akman U, Hortaçsu O. Micronization of ibuprofen by RESS. J Supercritical Fluids 2003; 26: 17-31.
70. Gosselin PM, Thibert R, Preda M, et al. Polymorphic properties of micronized carbamazepine produced by RESS. Int J Pharm 2003; 252: 225-33.
71. Thakur R, Gupta RB. Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process. Int J Pharm 2006; 308: 190-9.
72. Tandya A, Dehghani F, Foster NR. Micronization of cyclosporine using dense gas techniques. J Supercritical Fluids 2006; 37: 272-8.
73. Matsuyama K, Mishima K, Hayashi KI, et al. Formation of microcapsules of medicines by the rapid expansion of a supercritical solution with a nonsolvent. J Applied Polymer Sci 2003; 89: 742-52.
74. Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carr Syst 2001; 18: 173-99.
75. 2 antisolvent with enhanced mass transfer. Int J Pharm 2001; 228: 19-31.
76. Shekunov BY, Sun Y, Astracharchik E, et al. Optical characterisation and mechanism of antisolvent precipitation in turbulent flow. Proc 7th Meeting on Supercritical Fluids, Antibes, France 2000; 1: 65-70.
77. 2. J Supercritical Fluids 2003; 27: 73-83.
78. Martín A, Bouchard A, Hofland GW, et al. Mathematical modeling of the mass transfer from aqueous solutions in a supercritical fluid during particle formation. J Supercritical Fluids 2007; 41: 126-37.
79. Bałdyga J, Henczka M, Shekunov BY. Fluid dynamics, mass transfer, and particle formation in supercritical fluids. In: York P, Kampella UB, Shekunov BY, Eds. Supercritical Fluid Technology for Drug Product Development 2004; pp.87-152.
80. Shekunov BY, Bałdyga J, York P. Particle formation by mixing with supercritical antisolvent at high Reynolds numbers. Chem Eng Sci 2001; 56: 2421-33.
81. Bałdyga J, Czarnocki R, Shekunov BY, et al. Particle formation in supercritical fluids-scale up problem. Chem Eng Res and Design 2010; 88: 331-41.
82. Weidner E, Knez Ž, Novak Z, Inventors. Process for preparing particles or powders. European patent EP 0744992 Patent WO 95/21688. 1995.
83. Mandzuka Z, Knez Z. Influence of temperature and pressure during PGSS (TM) micronization and storage time on degree of crystallization and crystal forms of monostearate and tristearate. J Supercritical Fluids 2008; 45: 102-11.
84. Lubary M, de Loos TW, ter Horst JH, et al. Production of microparticles from milk products using the supercritical solvent melt micronization (ScMM) process. J Supercritical Fluids 2011; 55: 1079-88.
85. de Paz E, Martín A, Duarte CMM, et al. Formulation of β-carotene with poly-(ε-caprolactones) by PGSS process. Powder Tech 2012; 217: 77-83.
86. Sievers RE, Karst U, Milewski PD, et al. Formation of aqueous small droplet aerosols assisted by supercritical carbon dioxide. Aerosol Sci and Tech 1999; 30: 3-15.
87. Reverchon E. Supercritical-assisted atomization to produce microand/ or nanoparticles of controlled size and distribution. Ind and Eng Chem Res 2002; 41: 2405-11.
88. Shekunov BY, Chattopadhyay P, Seitzinger J, et al. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res 2006; 23: 196-204.
89. Chattopadhyay P, Huff R, Shekunov BY. Drug encapsulation using supercritical fluids extraction of emulsions. J Pharm Sci 2006; 95: 667-79.
90. Porta GD, Falco N, Reverchon E. Continuous supercritical emulsions extractions: a new technology for biopolymer microparticles production. Biotech & Bioeng 2011; 108: 676-86.
91. Chattopadhyay P, Shekunov BY, Yim D, et al. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Del Rev 2007; 59: 444-53.
92. Sun Y, Jiang H, Dong X, et al. SCF particle design for novel DDS preparations. 10th International Symposium on Supercritical Fluids, 2012; Available from: http: //issf2012.com/handouts/documents/165_000.pdf [accessed 12 Oct, 2012]
93. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 2006; 321: 1-11.
94. Liu P, Rong XY, Laru J, et al. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int J Pharm 2011; 411: 215-22.
95. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm 2006; 62: 3-16.
96. Chan HK, Kwok PC. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Del Rev 2011; 63: 406-16.
97. Reverchon E, De Marco I, Caputo G, et al. Pilot scale micronization of amoxicillin by supercritical antisolvent precipitation. J Supercritical Fluids 2003; 26: 1-7.
98. Thakur R, Gupta RB. Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process. Int J Pharm 2006; 308: 190-9.
99. Reverchon E, Antonacci A. Drug-polymer microparticles produced by supercriticalassisted atomization. Biotech and Bioeng 2007; 97: 1626-37.
100. Kim YH, Shing KS. Supercritical fluid-micronized ipratropium bromide for pulmonary drug delivery. Powder Tech 2008; 182: 25-32.
101. Kang Y, Yin G, Ouyang P, et al. Preparation of PLLA/PLGA microparticles using solution enhanced dispersion by supercritical fluids (SEDS). J Colloid Interface Sci 2008; 322: 87-94.
102. Sun Y. Protein microspheres for pulmonary drug delivery. Frontiers of Chem Eng in China 2010; 4: 82-6.
103. Kim MS, Kim JS, Park HJ, et al. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomed 2011; 6: 2997-3009.
104. 2: Prevention of excessive agglomeration. J Supercritical Fluids 2011; 59: 117-23.
105. Pourasghar M, Fatemi S, Vatanara A, et al. Production of ultrafine drug particles through rapid expansion of supercritical solution; a statistical approach. Powder Tech 2012; 225: 21-6.
106. Campardelli R, Adami R, Della Porta G, et al. Nanoparticle precipitation by supercritical assisted injection in a liquid antisolvent. Chem Eng J 2012; 192: 246-51.
107. De M, Ghosh PS, Rotello VM. Applications of nanoparticles in biology. Adv Mater 2008; 20: 4225-41.
108. 2 flow rate. Powder Tech 2010; 200: 246-53.
109. Shinde AJ. Solubilization of poorly soluble drugs: a review. Pharm Rev Latest Rev 2007; 5: 1-13.
110. Richard J. Supercritical fluid technology-application to drug delivery, Future Drug Delivery 2006; 61-3.
111. Balshaw DM, Philbert M, Suk WA. Research strategies for safety evaluation of nanomaterials, Part III: Nanoscale technologies for assessing risk and improving public health. Toxicol Sci 2005; 88: 298-306.
112. Bawa R. Nanopharmaceuticals for drug delivery-a review. Drug delivery 2009; 3: 122-7.
113. Aguiar AJ, Zelmer JE. Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. J Pharm Sci 1969; 58: 983-7.
114. Rodriguez-Spong B, Price CP, Jayasankar A, et al. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv Drug Del Rev 2004; 56: 241-74.
115. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev 2004; 56: 335-47.
116. Chemburkar SR, Bauer J, Deming K, et al. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. J Org Process Res Dev 2000; 4: 413-17.
117. Raw AS, Furness MS, Gill DS, et al. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv Drug Del Rev 2004; 56: 397-414.
118. Brittain HG, Grant DJR, Myrdal PB. Effects of polymorphism and solid-state solvation on solubility and dissolution rate. In: Brittain H (Ed), Polymorphism in Pharmaceutical Sciences, Drugs and Pharm Sci 1999; 95: 279-330.
119. Yu LX, Furness MS, Raw A, et al. Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm Res 2003; 20: 531-36.
120. Lu Y, Du G. Polymorphic drugs. People's Medical Pub 2009; 294-329.
121. Bolten D, Türk M. Micronisation of carbamazepine through rapid expansion of supercritical solution (RESS). J Supercritical Fluids 2012; 62: 32-40.
122. Kayrak D, Akman U, Hortacsu O. Micronization of ibuprofen by RESS. J Supercritical Fluids 2003; 26: 17-31.
123. Rodrigues MA, Padrela L, Geraldes V, et al. Theophylline polymorphs by atomization of supercritical antisolvent induced suspensions. J Supercritical Fluids 2011; 58: 303-12.
124. Yeo SD, Lee JC. Crystallization of sulfarnethizole using the supercritical and liquid antisolvent processes. J Supercritical Fluids 2004; 30: 315-23.
125. Tien YC, Su CS, Lien LH, et al. Recrystallization of erlotinib hydrochloride and fulvestrant using supercritical antisolvent process. J Supercritical Fluids 2010; 55: 292-9.
126. De Zordi N, Kikic I, Moneghini M, et al. Piroxicam solid state studies after processing with SAS technique. J Supercritical Fluids 2010; 55: 340-7.
127. Su CS, Tang M, Chen YP. Micronization of nabumetone using the rapid expansion of supercritical solution (RESS) process. J Supercritical Fluids 2009; 50: 69-76.
128. Bouchard A, Jovanović N, Hofland GW, et al. Ways of manipulating the polymorphism of glycine during supercritical fluid crystallization. J Supercritical Fluids 2008; 44: 422-32.
129. Reverchon E, Della Porta G. Terbutaline micro particles suitable for aerosol delivery produced by supercritical assisted atomization. Int J Pharm 2003; 258: 1-7.
130. Rehman M, Shekunov BY, York P, et al. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sci 2004; 22: 1-17.
131. Tozuka Y, Kawanda D, Oguchi T, et al. Supercritical carbon dioxide treatment as a method for polymorph preparation of deoxycholic acid. Int J Pharm 2003; 263: 45-50.
132. Velaga SP, Berger R, Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide. Pharm Res 2002; 19: 1564-71.
133. Shinozaki H, Oguchi T, Suzuki S, et al. Micronization and polymorphic conversion of tolbutamide and barbital by rapid expansion of supercritical solutions. Drug Dev Ind Pharm 2006; 32: 877-91.
134. Velaga SP, Ghaderi R, Carlfors J. Preparation and characterisation of hydrocortisone particles using a supercritical fluids extraction process. Int J Pharm 2002; 231: 155-66.
135. Reverchon E, De Marco I, Della Porta G. Rifampicin microparticles production by supercritical antisolvent precipitation. Int J Pharm 2002; 243: 83-91.
136. Van Nijlen T, Brennan K, Van den Mooter G, et al. Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. Int J Pharm 2003; 254: 173-81.
137. Goldberg I, Becker Y. Polymorphs of tamoxifen citrate: detailed structural characterization of the stable form. J Pharm Sci 1987; 76: 259-64.
138. Kruger GJ, Gafner G. The crystal structures of polymorphs I and III of sulphathiazole. Acta Cryst 1972; B28: 272-283.
139. 2. Pharm Res 2001; 18: 682-8.
140. 2: a novel technique for the separation of chiral drugs. J Pharm Sci 1999; 88: 786-91.
141. Sekhon BS. Separation of pharmaceutical enantiomers using supercritical fluid technology. Int J Pharm Tech Res 2010; 2: 1595-602.
142. Tiwari R, Tiwari G, Srivastava B, et al. Solid dispersions: an overview to modify bioavailability of poorly water-soluble drugs. Int J Pharm Tech Res 2009; 4: 1338-49.
143. Dhirendra K, Lewis S, Udupa N, et al. Solid dispersions: an overview. Pak J Pharm Sci 2009; 22: 234-46.
144. Mishra DK, Dhote V, Bhatnagar P, et al. Engineering solid lipid nanoparticles for improved drugdelivery: promises and challenges of translational research. Drug Del and Transl Res 2012; 2: 238-253.
145. Salmaso S, Elvassore N, Bertucco A, et al. Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-assisted melting atomization process. J Pharm Sci 2009; 98: 640-9.
146. Huang LF, Tong WQ. Impact of solid state properties on develop ability assessment of drug candidates. Adv Drug Del Rev 2004; 56: 321-34.
147. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVPK30 by conventional solvent evaporation and supercritical methods. Int J Pharm 2004; 272: 1-10.
148. Lim RTY, Ng WK, Tan RBH. Dissolution enhancement of indomethacin via amorphization using co-milling and supercritical coprecipitation processing. Powder Tech 2012; Available online 9 July 2012: http: //www.sciencedirect.com/science/article/pii/S00325910 12004743 [accessed 12 Oct 2012].
149. Pathak P, Meziam MJ, Desai T, et al. Formation and stabilization of ibuprofen nanoparticles in supercritical fluid processing. J Supercritical Fluids 2006, 37: 279-26.
150. Gong K, Viboonkiat R, Rehman IU, et al. Formulation and characterization of porous indomethacin-PVP coprecipitate prepared using solvent-free supercritical fluid processing. J Pharm Sci 2005; 94: 2583-90.
151. Charoenchaitrakool M, Dehghani F, Foster NR. Utilization supercritical carbon dioxide for complex formation of ibuprofen methyl-β-cyclodextrin. Int J Pharm 2002; 239: 103-12.
152. Bandi N, Wei W, Roberts CB, et al. Preparation of budesonideand indomethacin-hydroxypropyl-β-cyclodextrin (HPβCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur J Pharm Sci 2004; 23: 159-68.
153. Al-Marzouqi AH, Shehatta I, Jobe B, et al. Phase solubility and inclusion complex of itraconazole with β-cyclodextrin using supercritical carbon dioxide. J Pharm Sci 2006; 95: 292-304.
154. Chen AZ, Li Y, Chau FT, et al. Microencapsulation of puerarin nanoparticles by poly(l-lactide) in a supercritical CO2 process. Acta Biomaterialia 2009; 5: 2913-19.
155. Sanganwar GP, Gupta RB. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm 2008; 360: 213-8.
156. Madieh S, Simone M, Wilson W, et al. Investigation of drugporous adsorbent interactions in drug mixtures with selected porous adsorbents. J Pharm Sci 2007; 96: 851-63.
157. Shekunov BY. Production of powders for respiratory drug delivery. In: York P, Kompella UB, Shekunov BY, Eds. Supercritical fluid technology for drug product development 2004; pp.247-82.
158. Sievers RE, Quinn BP, Cape SP, et al. Near-critical fluid micronization of stabilized vaccines, antibiotics and anti-virals. J Supercritical Fluids 2007; 42: 385-91.
159. Burger JL, Cape SP, Braun CS, et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv 2008; 21: 25-34.
160. Lin WH, Griffin DE, Rota PA, et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. PNAS 2011; 108: 2987-92.
161. Cape SP, Villa JA, Huang ETS, et al. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res 2008; 25: 1967-90.
162. Kluge J, Fusaro F, Casas N, et al. Production of PLGA micro-and nano composites by supercritical fluid extraction of emulsions: I. Encapsulation of lysozyme. J Supercritical Fluids 2009; 50: 327-335.
163. 2 in the fabrication of polymer systems for drug delivery and tissue engineering. Adv Drug Del Rev 2008; 60: 373-87.
164. Caliceti P, Salmaso S, Elvassore N, et al. Effective protein release from PEG/PLA nano-particles produced by compressed gas antisolvent precipitation techniques. J Contr Rel 2004; 94: 195-205.
165. Salmaso S, Elvassore N, Bertucco A, et al. Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-assisted melting atomization process. J Pharm Sci 2009; 98: 640-50.
166. Gillis J. FDA approves inhalable insulin. Washington Post, 28 Jan 2006.
167. Sun Y, inventor; CNANE. A supercritical fluid method of preparing dry powder inhaler of recombinant human insulin. Chinese Invention Patent ZL 2006 1 0015666. X, 15 September 2006.
168. Muthukumaran P, Chordia L. Scale-up considerations in supercritical anti-solvent processes: atomization and mixing. Proceedings of 6th International Symposium on Supercritical Fluids, Versailles (France) 28-30 April 2003. Available from: http: //www.isasf.net/fileadmin/files/Docs/Versailles/Papers/Md13.pdf [accessed Oct 12, 2012].
169. Perrut M. Sterilization and virus inactivation by supercritical fluids (a review). J Supercritical Fluids 2012; 66: 359-71.
170. Machida H, Takesue M, Smith RL Jr. Green chemical processes with supercritical fluids: properties, materials, separations and energy. J Supercritical Fluids 2011; 60: 2-15.
171. Drug delivery technology platform. Available from: http: //www.criticalpharmaceuticals.com/technology [accessed Oct 12, 2012]
172. XSprayMicroparticles launches high quality particulate GMP manufacturing to US and EU regulatory standards [updated Aug 20, 2009]. Available from: http: //www.prnewswire.com/newsreleases/ xspray-launches-gmp-production-facility-62272832.html [accessed Oct 12, 2012]
173. Adventrx and Pierre Fabre announce manufacturing agreement for Anx-188 drug substance [updated July 12, 2010]. Available from http: //www.supercritical-solutions.com/pub/Press_Release [accessed Oct 12, 2012]
174. A history of innovation. Available from: http: //www.ferro.com/Our+Products/Pharmaceuticals/About+Us/_Time +Line.htm [accessed Oct 12, 2012]
175. MAP Pharmaceuticals provides update following meeting with FDA for LEVADEX® (dihydroergotamine) new drug application [updated June 25, 2012]. Available from: http: //ir.mappharma.com/releasedetail.cfm? ReleaseID=686062 [accessed Oct 12, 2012]
176. 2010 Annual Report. Available from: http: //ir.mappharma.com/annuals.cfm [accessed Oct 12, 2012]